• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Protagonist`s PN-881 as IL-17 Antagonist Development Candidate

    ACCESSWIRE

    Protagonist to Announce IL-17 Antagonist Development Candidate

    ACCESSWIRE

    Protagonist Announces Positive Results from Iconic Psoriasis Study

    ACCESSWIRE

    Protagonist Reports Q3 2024 Results & Update

    ACCESSWIRE

    Protagonist to Present Final REVIVE Phase 2 Data at ASH 2024

    ACCESSWIRE

    Protagonist Reports Q2 2024 Results And Provides Corporate Update

    ACCESSWIRE

    Protagonist Reports Long Term Rusfertide Results At EHA2024 Congress

    ACCESSWIRE

    Protagonist At Jefferies Healthcare Conference 2024

    ACCESSWIRE

    Protagonist Presents Rusfertide Phase 2 REVIVE OLE Data At EHA 2024

    ACCESSWIRE

    Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

    PRESS RELEASE

    Protagonist Q1 2024 Results, Corporate Update

    ACCESSWIRE

    Protagonist At Citizens, CapOne Biotech Conferences

    ACCESSWIRE

    Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment

    ACCESSWIRE

    Protagonist Announces Closing of Worldwide Rusfertide License

    ACCESSWIRE

    Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year

    ACCESSWIRE

    Protagonist Therapeutics to Participate in Upcoming Investor Conferences

    ACCESSWIRE

    Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results

    ACCESSWIRE

    New England Journal of Medicine Publishes Results of Positive Ph 2 of Rusfertide

    ACCESSWIRE

    Protagonist Therapeutics Reports Granting of Inducement Awards

    ACCESSWIRE

    Takeda wagers $300M on Protagonist’s PhIII rare disease drug

    ENDPTS

    Takeda and Protagonist Therapeutics, Inc. Enter into Agreement for Rusfertide

    ACCESSWIRE

    Protagonist to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024

    PRESS RELEASE

    Protagonist Therapeutics to Participate in 42nd Annual J.P. Morgan Conference

    ACCESSWIRE

    Protagonist Earns $10 Million Payment for Phase 2bof JNJ-2113

    ACCESSWIRE

    Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at ASH

    ACCESSWIRE

    Protagonist Announces Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113

    ACCESSWIRE

    Protagonist Therapeutics Reports Granting of Inducement Awards

    ACCESSWIRE

    Protagonist Ranked in Top 3% of Fastest-Growing Companies in North America

    ACCESSWIRE

    Protagonist Announces Abstracts Selected for Oral and Poster Presentations

    ACCESSWIRE

    Protagonist Reports Third Quarter 2023 Financial Results

    ACCESSWIRE

    Protagonist Therapeutics to Participate in Upcoming Investor Conferences

    ACCESSWIRE

    Protagonist Announces Achievement of $50M Milestone Event

    ACCESSWIRE

    Protagonist Announces Appointment of Daniel Swisher to Its Board of Directors

    ACCESSWIRE

    Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications

    ACCESSWIRE

    Protagonist Therapeutics Reports Granting of Inducement Award

    ACCESSWIRE

    Protagonist Therapeutics to Present at Upcoming Investor Conferences

    ACCESSWIRE

    Protagonist Therapeutics Reports Granting of Inducement Award

    ACCESSWIRE

    Protagonist Receives $34 Million from Warrant Exercises

    ACCESSWIRE

    Protagonist Reports Second Quarter 2023 Financial Results

    ACCESSWIRE

    Protagonist Therapeutics Reports Granting of Inducement Award

    ACCESSWIRE

    J&J psoriasis drug licensed from Protagonist doesn`t top competition

    ENDPTS

    Durability of Response of Rusfertide in Polycythemia Vera Featured at EHA

    ACCESSWIRE

    Protagonist Announces Acceptance of Abstract for Oral Presentation at EHA

    ACCESSWIRE

    Protagonist to Participate in the 2023 Jefferies Healthcare Conference

    ACCESSWIRE

    Protagonist Reports Positive Results from Ph1 &Preclinical Studies Oral JNJ-2113

    PR NEWSWIRE

    Protagonist Therapeutics Announces Presentations at the 2023

    PR NEWSWIRE

    Protagonist Therapeutics to Participate in the JMP Securities Life Conference

    PR NEWSWIRE

    Protagonist Reports 1Q FYR 2023 and Provides Corporate Update

    PR NEWSWIRE

    Protagonist Announces Pricing of $100 Million Public Offering of Shares

    ACCESSWIRE

    Protagonist Announces Results from REVIVE Study of Rusfertide

    ACCESSWIRE

    Protagonist Reports Fourth Quarter and Full Year 2022 Financial Results

    ACCESSWIRE

    Protagonist`s story turns for the better on psoriasis data

    FIERCE BIOTECH

    Protagonist Announces Positive Results for Ph2b FRONTIER 1 Trial of Oral IL-23

    PR NEWSWIRE

    Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan

    PRNEWSWIRE

    Protagonist to Participate in the JMP Securities Hematology and Oncology Summit

    PRNEWSWIRE

    Protagonist Therapeutics Reports Granting of Inducement Award

    PRNEWSWIRE

    Drugs up for sale, on the shelf in biotech pipeline clear-outs

    FIERCEBIOTECH

    Protagonist Therapeutics Announces Presentations at the ASH 2022 Meeting

    PRNEWSWIRE

    Protagonist Announces Appointment of Arturo Molina as CMO

    PRNEWSWIRE

    Protagonist Reports Second Quarter 2022 Financial Results

    PRNEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.